MedTrace Logo

A Study of TYRA-300 in Children With Achondroplasia: BEACH301

NCT06842355 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2026-04-24

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability, and identify potentially effective dose(s) of TYRA-300 in children with achondroplasia with open growth plates.

Conditions

Interventions

DRUG

TYRA-300 0.125 mg/kg

Initial dose level of TYRA-300 per protocol, subsequent dose level escalations will occur based on criteria outlined in the protocol.

DRUG

TYRA-300 0.25 mg/kg

Subsequent dose level escalations will occur based on criteria outlined in the protocol.

DRUG

TYRA-300 0.375 mg/kg

Subsequent dose level escalations will occur based on criteria outlined in the protocol.

DRUG

TYRA-300 0.50 mg/kg

Subsequent dose level escalations will occur based on criteria outlined in the protocol.

Sponsors & Collaborators

  • Tyra Biosciences, Inc

    lead INDUSTRY

Principal Investigators

  • Doug Warner, MD · Tyra Biosciences

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
3 Years
Max Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-04
Primary Completion
2030-01-31
Completion
2030-06-30
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06842355 on ClinicalTrials.gov